seed
Stage
About
Immugenia is an early stage immuno-oncology company developing a novel CAR therapy approach by engineering hematopoietic stem cells to treat cancer and prevent relapses, focusing on selective CAR expression in T and NK cells and advancing in vivo CAR therapy delivery.
Explore Immugenia's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.